Handbook of Incretin-based Therapies in Type 2 Diabetes (eBook, PDF)
53,49 €
inkl. MwSt.
Sofort per Download lieferbar
Handbook of Incretin-based Therapies in Type 2 Diabetes (eBook, PDF)
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
This concise handbook provides an overview of incretin-based therapies and guidance for incorporating them into the treatment of type 2 diabetes. Chapters include landmark clinical trials and international treatment guidelines in order to update readers with all major advances in the field. An ideal resource for medical professionals that treat patients with type 2 diabetes in hospital and clinical settings.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 1.49MB
- Upload möglich
Andere Kunden interessierten sich auch für
- Winston CrastoHandbook of Insulin Therapies (eBook, PDF)53,49 €
- Type 2 Diabetes Mellitus: (eBook, PDF)213,99 €
- Managing Gastrointestinal Complications of Diabetes (eBook, PDF)53,49 €
- Miles FisherEssentials of SGLT2 Inhibitors in Diabetes (eBook, PDF)53,49 €
- Managing Diabetic Eye Disease in Clinical Practice (eBook, PDF)53,49 €
- Diabetes Mellitus in Developing Countries and Underserved Communities (eBook, PDF)96,29 €
- Perez Kisakye KatambalaThe association between circulating levels of myeloperoxidase and type 2 diabetes in the Malmö diet and cancer cohort. An Assessment (eBook, PDF)0,00 €
-
-
-
This concise handbook provides an overview of incretin-based therapies and guidance for incorporating them into the treatment of type 2 diabetes. Chapters include landmark clinical trials and international treatment guidelines in order to update readers with all major advances in the field. An ideal resource for medical professionals that treat patients with type 2 diabetes in hospital and clinical settings.
Produktdetails
- Produktdetails
- Verlag: Springer International Publishing
- Erscheinungstermin: 7. Juni 2016
- Englisch
- ISBN-13: 9783319089829
- Artikelnr.: 46926283
- Verlag: Springer International Publishing
- Erscheinungstermin: 7. Juni 2016
- Englisch
- ISBN-13: 9783319089829
- Artikelnr.: 46926283
Stephen Gough is Professor of Diabetes at the University of Oxford and Consultant Physician at the Oxford University Hospitals NHS Trust. Professor Gough graduated in medicine from Leeds University Medical School, where he was later awarded a higher degree Doctorate in Medicine, which focused on cardiac dysfunction and abnormalities in coagulation and fibrinolysis present at the time of diagnosis of type 2 diabetes. He is currently based at the Oxford Centre for Diabetes, Endocrinology and Metabolism, where he is a practicing clinician in diabetes. His research interests and ongoing research studies include translational aspects of diabetes, with a focus on the physiology of islet cell and whole organ pancreas transplantation, incretin biology, and incretin therapies in diabetes. Professor Gough has previously had a strong interest in the genetic susceptibility to autoimmunity and this work has been extended into his work on pancreas transplantation. He has published his research extensively in peer-reviewed journals and has contributed to many national and international conferences and books on diabetes. In recent years, Professor Gough has helped develop translation research in diabetes in Oxford through a number of local and national initiatives, including the Oxford Biomedical Research Centre, and he is Clinical Lead in Diabetes for the Oxford Academic Health Science Network and the Oxford Local Clinical Research Network.
Addendum
Since editing this book, Professor Gough has taken up the position of Senior Principal Clinical Scientist with Novo Nordisk. He continues as Visiting Professor of Diabetes at the University of Oxford and Honorary Consultant with the Oxford University Hospitals NHS Trust.
Addendum
Since editing this book, Professor Gough has taken up the position of Senior Principal Clinical Scientist with Novo Nordisk. He continues as Visiting Professor of Diabetes at the University of Oxford and Honorary Consultant with the Oxford University Hospitals NHS Trust.
1. Introduction and disease overview References
2. Incretin hormones as a target for therapy Incretin hormone physiology The incretin-producing cell GIP and GLP-1 action Measurement of the incretin hormones Incretin action in healthy individuals Incretin action in patients with type 2 diabetes Therapeutics application References
3. Glucagon-like peptide receptor agonists Introduction GLP-1 receptor agonists Extrapancreatic effects GLP-1 receptor agonists Pancreatic safety Perspectives References
4. Dipeptidyl peptidase-4 inhibitors Introduction Pharmacokinetics and pharmacodynamics Efficacy Combination therapy Use in specific patient populations Conclusions References
5. Global position and recommendations for use Introduction American Association of Clinical Endocrinologists/American College of Endocrinology American Diabetes Association /European Association for the Study of Diabetes International Diabetes Federation National Institute of Health and Care Excellence Using incretin-based therapies in clinical practice Availability and licences References
6. Future and emerging therapies Introduction Once-weekly agents under investigation Subcutaneous implants Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors Other indications for incretin therapies DPP-4 inhibitors References
2. Incretin hormones as a target for therapy Incretin hormone physiology The incretin-producing cell GIP and GLP-1 action Measurement of the incretin hormones Incretin action in healthy individuals Incretin action in patients with type 2 diabetes Therapeutics application References
3. Glucagon-like peptide receptor agonists Introduction GLP-1 receptor agonists Extrapancreatic effects GLP-1 receptor agonists Pancreatic safety Perspectives References
4. Dipeptidyl peptidase-4 inhibitors Introduction Pharmacokinetics and pharmacodynamics Efficacy Combination therapy Use in specific patient populations Conclusions References
5. Global position and recommendations for use Introduction American Association of Clinical Endocrinologists/American College of Endocrinology American Diabetes Association /European Association for the Study of Diabetes International Diabetes Federation National Institute of Health and Care Excellence Using incretin-based therapies in clinical practice Availability and licences References
6. Future and emerging therapies Introduction Once-weekly agents under investigation Subcutaneous implants Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors Other indications for incretin therapies DPP-4 inhibitors References
1. Introduction and disease overviewReferences
2. Incretin hormones as a target for therapyIncretin hormone physiology The incretin-producing cellGIP and GLP-1 actionMeasurement of the incretin hormonesIncretin action in healthy individualsIncretin action in patients with type 2 diabetesTherapeutics applicationReferences
3. Glucagon-like peptide receptor agonists Introduction GLP-1 receptor agonists Extrapancreatic effects GLP-1 receptor agonists Pancreatic safety Perspectives References
4. Dipeptidyl peptidase-4 inhibitors Introduction Pharmacokinetics and pharmacodynamics Efficacy Combination therapy Use in specific patient populations Conclusions References
5. Global position and recommendations for use Introduction American Association of Clinical Endocrinologists/American College of EndocrinologyAmerican Diabetes Association /European Association for the Study of DiabetesInternational Diabetes Federation National Institute of Health and Care Excellence Using incretin-based therapies in clinical practice Availability and licences References
6. Future and emerging therapies Introduction Once-weekly agents under investigation Subcutaneous implants Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors Other indications for incretin therapiesDPP-4 inhibitorsReferences
2. Incretin hormones as a target for therapyIncretin hormone physiology The incretin-producing cellGIP and GLP-1 actionMeasurement of the incretin hormonesIncretin action in healthy individualsIncretin action in patients with type 2 diabetesTherapeutics applicationReferences
3. Glucagon-like peptide receptor agonists Introduction GLP-1 receptor agonists Extrapancreatic effects GLP-1 receptor agonists Pancreatic safety Perspectives References
4. Dipeptidyl peptidase-4 inhibitors Introduction Pharmacokinetics and pharmacodynamics Efficacy Combination therapy Use in specific patient populations Conclusions References
5. Global position and recommendations for use Introduction American Association of Clinical Endocrinologists/American College of EndocrinologyAmerican Diabetes Association /European Association for the Study of DiabetesInternational Diabetes Federation National Institute of Health and Care Excellence Using incretin-based therapies in clinical practice Availability and licences References
6. Future and emerging therapies Introduction Once-weekly agents under investigation Subcutaneous implants Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors Other indications for incretin therapiesDPP-4 inhibitorsReferences
1. Introduction and disease overview References
2. Incretin hormones as a target for therapy Incretin hormone physiology The incretin-producing cell GIP and GLP-1 action Measurement of the incretin hormones Incretin action in healthy individuals Incretin action in patients with type 2 diabetes Therapeutics application References
3. Glucagon-like peptide receptor agonists Introduction GLP-1 receptor agonists Extrapancreatic effects GLP-1 receptor agonists Pancreatic safety Perspectives References
4. Dipeptidyl peptidase-4 inhibitors Introduction Pharmacokinetics and pharmacodynamics Efficacy Combination therapy Use in specific patient populations Conclusions References
5. Global position and recommendations for use Introduction American Association of Clinical Endocrinologists/American College of Endocrinology American Diabetes Association /European Association for the Study of Diabetes International Diabetes Federation National Institute of Health and Care Excellence Using incretin-based therapies in clinical practice Availability and licences References
6. Future and emerging therapies Introduction Once-weekly agents under investigation Subcutaneous implants Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors Other indications for incretin therapies DPP-4 inhibitors References
2. Incretin hormones as a target for therapy Incretin hormone physiology The incretin-producing cell GIP and GLP-1 action Measurement of the incretin hormones Incretin action in healthy individuals Incretin action in patients with type 2 diabetes Therapeutics application References
3. Glucagon-like peptide receptor agonists Introduction GLP-1 receptor agonists Extrapancreatic effects GLP-1 receptor agonists Pancreatic safety Perspectives References
4. Dipeptidyl peptidase-4 inhibitors Introduction Pharmacokinetics and pharmacodynamics Efficacy Combination therapy Use in specific patient populations Conclusions References
5. Global position and recommendations for use Introduction American Association of Clinical Endocrinologists/American College of Endocrinology American Diabetes Association /European Association for the Study of Diabetes International Diabetes Federation National Institute of Health and Care Excellence Using incretin-based therapies in clinical practice Availability and licences References
6. Future and emerging therapies Introduction Once-weekly agents under investigation Subcutaneous implants Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors Other indications for incretin therapies DPP-4 inhibitors References
1. Introduction and disease overviewReferences
2. Incretin hormones as a target for therapyIncretin hormone physiology The incretin-producing cellGIP and GLP-1 actionMeasurement of the incretin hormonesIncretin action in healthy individualsIncretin action in patients with type 2 diabetesTherapeutics applicationReferences
3. Glucagon-like peptide receptor agonists Introduction GLP-1 receptor agonists Extrapancreatic effects GLP-1 receptor agonists Pancreatic safety Perspectives References
4. Dipeptidyl peptidase-4 inhibitors Introduction Pharmacokinetics and pharmacodynamics Efficacy Combination therapy Use in specific patient populations Conclusions References
5. Global position and recommendations for use Introduction American Association of Clinical Endocrinologists/American College of EndocrinologyAmerican Diabetes Association /European Association for the Study of DiabetesInternational Diabetes Federation National Institute of Health and Care Excellence Using incretin-based therapies in clinical practice Availability and licences References
6. Future and emerging therapies Introduction Once-weekly agents under investigation Subcutaneous implants Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors Other indications for incretin therapiesDPP-4 inhibitorsReferences
2. Incretin hormones as a target for therapyIncretin hormone physiology The incretin-producing cellGIP and GLP-1 actionMeasurement of the incretin hormonesIncretin action in healthy individualsIncretin action in patients with type 2 diabetesTherapeutics applicationReferences
3. Glucagon-like peptide receptor agonists Introduction GLP-1 receptor agonists Extrapancreatic effects GLP-1 receptor agonists Pancreatic safety Perspectives References
4. Dipeptidyl peptidase-4 inhibitors Introduction Pharmacokinetics and pharmacodynamics Efficacy Combination therapy Use in specific patient populations Conclusions References
5. Global position and recommendations for use Introduction American Association of Clinical Endocrinologists/American College of EndocrinologyAmerican Diabetes Association /European Association for the Study of DiabetesInternational Diabetes Federation National Institute of Health and Care Excellence Using incretin-based therapies in clinical practice Availability and licences References
6. Future and emerging therapies Introduction Once-weekly agents under investigation Subcutaneous implants Investigational DPP-4 inhibitors and fixed-dose combination with SGLT2 inhibitors Other indications for incretin therapiesDPP-4 inhibitorsReferences